国内首款治疗儿童白血病的CAR-T获批上市；没能“嫁入”A股上市公司，海纳医药递表港交所｜掘金创新药

Group 1 - The core viewpoint of the article highlights the recent performance of the innovative drug sector, indicating a market correction phase after a strong rally, with significant declines in stock prices for leading companies like 康方生物 and 再鼎医药 [5][6][4] - The innovative drug index and related ETFs have shown declines, with the Hang Seng Healthcare Index down by 2.39% and the Hong Kong innovative drug ETF down by 3.92% over the week [4][5] - Recent clinical trial results for 再鼎医药's gastric cancer drug 贝玛妥珠单抗 were disappointing, leading to a halt in its clinical study due to insufficient efficacy [5][6] Group 2 - 海纳医药 has submitted an IPO application to the Hong Kong Stock Exchange after failing to complete a major asset restructuring to enter the A-share market [7][8] - The company primarily generates revenue from its CXO services, with 398 ongoing CXO projects as of mid-2025 [7] - 海纳医药's revenue for 2024 is projected at 425 million yuan, reflecting a year-on-year growth of 3.65%, but its net profit is expected to decline by 27% [8] Group 3 - The first CAR-T therapy for treating pediatric leukemia, 普基仑赛, has been approved for market release in China, marking a significant milestone in innovative drug development [13][12] - The approval of 普基仑赛 follows a series of clinical trials and regulatory reviews, emphasizing its potential in treating acute B-cell leukemia in children aged 3 to 21 [13][12] - The article notes that this is the fifth CD19-targeting CAR-T product approved in China, indicating a growing market for such therapies [14]